Drug discovery

Exogene is a biotechnology company accelerating the discovery of T-cell-receptor (TCR)- based cancer immunotherapies for solid tumours by combining deep learning and high-throughput TCR-antigen screening. Their mission is to develop better TCR-based cancer immunotherapies, faster and at a fraction of the cost.

Focus: Drug discovery platform 

Team: Federio Paoletti (CEO) and Andrea Mambrini (CTO)

Website: https://exogene.co.uk/ 

Be part of SBC Catalyser Programme!

Spaces are limited to 10 companies per cohort. Contact Marco to get more information on our next programme in spring 2024.

Contact Marco

We use cookies to improve our site experience. Press accept to agree to our Cookie Policy. If you decline, your information won’t be tracked when you visit this website. A single cookie will be used in your browser to remember your preference not to be tracked.